Impax licenses migraine drug rights from AstraZeneca
Impax to pay $130 million per quarter through 2012
Impax Pharmaceuticals said Wednesday that it obtained exclusive U.S. commercial rights to a drug for migraine headaches made by AstraZeneca.
Post a Comment
Footer Content
Retail Group
Events - Retail
Industry Guides, Research & Reports
International
footer
© 2012 Drug Store News. All Rights Reserved.